Search Results
The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study at ESC 2017.
Antiinflammatory Therapy and Cardiovascular Events
ESC Congress 2017 | Day 2 Highlights
ESC Congress 2017: Mary Norine Walsh, MD, FACC, Discusses CANTOS Trial
CANTOS Trial Recap with PI Paul Ridker, MD
Anti-inflammatory drug reduces heart attack risk: new study
Cardiovascular Outcomes for People Using Anticoagulation Strategies at ESC 2017
Canakinumab Case Study | Philip Conaghan
ACC 22: Secondary Analysis of CANTOS Finds LDL & HDL Predict Residual Risk of Atherosclerotic Events
Clinical Trial: Canakinumab for Alzheimer's Disease (NCT04795466)
Canakinumab’s cardiovascular benefits linked with hsCRP cuts
ESC TV at AHA 2018 - The Cardiovascular Inflammation Reduction Trial (CIRT)
